A novel cell-mediated immunotherapy is being developed according to the Leishmania strategy of vaccine delivery (Chang et al., 2016 Parasit Vectors. 9:396) against difficult-to-cure diseases, e. g. canine leishmaniasis in Italy. The current clinical management of this disease there entails prolonged treatments of sick dogs for 30 days with heavy daily dosage of very toxic drugs (antimonials/miltefosine) followed by a daily maintenance dose of allopurinol for life. Still, relapses of the disease are frequent within the first year. When applied appropriately, the immunotherapy appears to boost the feeble immunity expected to develop after chemotherapy. Work is on-going to see if it is robust enough to clear the infection completely from immunized dogs, and to enroll additional dogs for both prophylactic and therapeutic trials.
Immunotherapy of canine leishmaniasis by photodynamic vaccination / Manna, Laura. - (2017). (Intervento presentato al convegno 6th World Congress on Leishmaniasis tenutosi a Toledo, Spagna nel 16-20 Maggio 2017).
Immunotherapy of canine leishmaniasis by photodynamic vaccination
Manna
2017
Abstract
A novel cell-mediated immunotherapy is being developed according to the Leishmania strategy of vaccine delivery (Chang et al., 2016 Parasit Vectors. 9:396) against difficult-to-cure diseases, e. g. canine leishmaniasis in Italy. The current clinical management of this disease there entails prolonged treatments of sick dogs for 30 days with heavy daily dosage of very toxic drugs (antimonials/miltefosine) followed by a daily maintenance dose of allopurinol for life. Still, relapses of the disease are frequent within the first year. When applied appropriately, the immunotherapy appears to boost the feeble immunity expected to develop after chemotherapy. Work is on-going to see if it is robust enough to clear the infection completely from immunized dogs, and to enroll additional dogs for both prophylactic and therapeutic trials.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.